Business

Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista

Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista.

articleTodos Medical Ltd.December 27, 20214/company/todos-medical-ltd/news/todos-medical-records-record-weekly-covid-pcr-testing-volumes-at-provista
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista

About this update from Todos Medical Ltd.

[{"type":"text","content":"\n cPass neutralizing antibody testing seeing increasing demand, questions of infection-acquired immunity, vaccine-acquired immunity and booster shot durability emerge The Company also entered into a new laboratory services agreement with a New Jersey-based physician practice for COVID PCR testing and cPass neutralizing antibody testing New York, NY, and Tel Aviv, ISRAEL, Dec. 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its highly automated CLIA/CAP PCR and cPass neutralizing antibody COVID-19 testing laboratory Provista Diagnostics achieved consecutive record weekly COVID PCR testing volumes for the weeks of December 13, 2021 and December 20, 2021. The COVID PCR testing volumes were primarily driven by reference lab business from a New York-based PCR testing lab that could not fulfill the testing demand from its location. The Company also entered into a new laboratory services agreement with a New Jersey-based physician practice for COVID PCR Testing and COVID cPass neutralizing antibody testing. “The demand for PCR testing is rapidly increasing in pockets of the United States, and we expect this to continue beyond the holiday surge as individuals, schools and employers seek to create safe environments, especially in areas with low vaccination rates,” said Gerald E. Commissiong, President & CEO of Todos Medical, the parent company of Provista Diagnostics. “Given the pending ‘vaccine or test’ mandate from the Biden Administration that will impose testing requirements on the 38% of the US adult population that have yet to be fully vaccinated against COVID-19, we see the recent scarcity of testing combined with the pending mandate creating demand for a very significant increase in long-term institutional COVID PCR testing for Provista. When you add the Omicron variant’s ability to evade vaccine or infection-acquired immunity, and the challenges of access and reliability of rapid antigen tests that notoriously yield false negative results, COVID PCR testing with fast turnaround times is emerging as the most trusted and reliable source of information to know one’s COVID infection status.” Mr. Commissiong continued, “Further, when you combi...

More updates from Todos Medical Ltd.